SIREN : 799735063
HERMEDIQUAL is a French company founded 12 years ago, specialized in the sector Conseil pour les affaires et autres conseils de gestion. Based in GROSVILLE (50340), this company of category PME shows in 2021 a revenue of 108 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-04-18
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|
| Revenue | 107 636 € | 74 358 € | 86 609 € | 104 804 € | 95 925 € | 63 268 € |
| Net income | 30 511 € | 4 718 € | 13 478 € | 29 109 € | 22 923 € | 377 € |
| EBITDA | 35 778 € | 5 865 € | 16 452 € | 34 886 € | 26 944 € | -2 339 € |
| Net margin | 28.3% | 6.3% | 15.6% | 27.8% | 23.9% | 0.6% |
In 2021, HERMEDIQUAL achieves revenue of 108 k€. Over the period 2016-2021, the company shows strong growth with a CAGR (compound annual growth rate) of +11.2%. Vs 2020, growth of +45% (74 k€ -> 108 k€). After deducting consumption (-15 €), gross margin stands at 108 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 36 k€, representing 33.2% of revenue. Positive scissor effect: EBITDA margin improves by +25.4 pts, sign of improved operational efficiency. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 31 k€, i.e. 28.3% of revenue. This profit can be retained or distributed to shareholders.
107 636 €
107 651 €
35 778 €
35 671 €
30 511 €
33.2%
The debt ratio (= Financial debt / Equity x 100) stands at 6%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 4%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Cash flow represents 28.4% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
6.35%
4.276%
28.448%
0.0
18.5%
In 2021, the debt ratio of HERMEDIQUAL (6.35) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2021, the financial autonomy of HERMEDIQUAL (4.3%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2021, the repayment capacity of HERMEDIQUAL (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 302.88. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
302.88
0.0
In 2021, the liquidity ratio of HERMEDIQUAL (302.88) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2021, the interest coverage of HERMEDIQUAL (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 102 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 10 days. The gap of 92 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow. Overall, WCR represents 53 days of revenue, i.e. 16 k€ to permanently finance. Notable WCR improvement over the period (-44%), freeing up cash.
15 817 €
102 j
10 j
0 j
53 j
Based on 61 transactions of similar company sales
in 2021,
the value of HERMEDIQUAL is estimated at
87 192 €
(range 46 600€ - 189 777€).
With an EBITDA of 35 778€, the sector multiple of 3.1x is applied.
The price/revenue ratio is 0.54x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 61 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare HERMEDIQUAL with other companies in the same sector:
Voir toutes les statistiques du secteur Conseil pour les affaires et autres conseils de gestion
The revenue of HERMEDIQUAL in 2021 is 108 k€.
Yes, HERMEDIQUAL generated a net profit of 31 k€ in 2021.
The headquarters of HERMEDIQUAL is located in GROSVILLE (50340), in the department Manche.
The tax return of HERMEDIQUAL is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
HERMEDIQUAL operates in the sector Conseil pour les affaires et autres conseils de gestion (NAF code 70.22Z). See the 'Sector positioning' section above to compare the company with its competitors.